Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01280747 · ClinicalTrials.gov registry record
Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study
A clinical trial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Terminated
- Registry status
- 42
- Enrollment target
NCT01280747 is a clinical trial that was terminated before completion, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 42 participants.
The verdict
NCT01280747 was terminated before completion, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- TERMINATED
- Registry status
- 42 participants
- Enrollment target
Study Summary
The investigators hypothesize that fibromyalgia (FM) and painful diabetic peripheral neuropathy (pDPN) patients with access restrictions on pregabalin will lead to higher healthcare resource use and cost compared to patients without such restrictions on pregabalin in a naturalistic setting. The randomization will occur at the physician level and not the patient level.
Interventions
- OTHER prior authorization
- OTHER no prior authorization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01280747
The ClinicalTrials.gov registry entry for NCT01280747 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which prior authorization is the first listed.
NCT01280747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01280747 about?
NCT01280747 is a clinical study titled "Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study". The investigators hypothesize that fibromyalgia (FM) and painful diabetic peripheral neuropathy (pDPN) patients with access restrictions on pregabalin will lead to higher healthcare resource use and cost compared to patients without such restrictions on pregabalin in a naturalistic setting. The rand...
What is the current status of trial NCT01280747?
This trial is currently terminated. The enrollment target is 42 participants. The study started on 2011-01. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01280747?
The interventions under investigation include: prior authorization (OTHER), no prior authorization (OTHER).
Who is sponsoring clinical trial NCT01280747?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.